Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 2 von 9
Nature (London), 2016-01, Vol.529 (7586), p.351-357
2016
Volltextzugriff (PDF)

Details

Autor(en) / Beteiligte
Titel
Divergent clonal selection dominates medulloblastoma at recurrence
Ist Teil von
  • Nature (London), 2016-01, Vol.529 (7586), p.351-357
Ort / Verlag
England: Nature Publishing Group
Erscheinungsjahr
2016
Quelle
MEDLINE
Beschreibungen/Notizen
  • The development of targeted anti-cancer therapies through the study of cancer genomes is intended to increase survival rates and decrease treatment-related toxicity. We treated a transposon-driven, functional genomic mouse model of medulloblastoma with 'humanized' in vivo therapy (microneurosurgical tumour resection followed by multi-fractionated, image-guided radiotherapy). Genetic events in recurrent murine medulloblastoma exhibit a very poor overlap with those in matched murine diagnostic samples (<5%). Whole-genome sequencing of 33 pairs of human diagnostic and post-therapy medulloblastomas demonstrated substantial genetic divergence of the dominant clone after therapy (<12% diagnostic events were retained at recurrence). In both mice and humans, the dominant clone at recurrence arose through clonal selection of a pre-existing minor clone present at diagnosis. Targeted therapy is unlikely to be effective in the absence of the target, therefore our results offer a simple, proximal, and remediable explanation for the failure of prior clinical trials of targeted therapy.

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX